AstraZeneca

Latest news

• 
  AstraZeneca deepens Summit ties on ADC-bispecific cancer combo testing pact (opens in a new tab)

  Pharmaceutical Technology · Oct 2, 2026

• 
  Sanofi, Regeneron Expand Immunology Alliance With New Antibodies (opens in a new tab)

  Zacks · Oct 2, 2026

• 
  Summit Teams Up With Daiichi Sankyo, AstraZeneca For Cancer Therapy Trial – CEO Calls It An ‘Important Expansion’ (opens in a new tab)

  Stocktwits · Oct 2, 2026

• 
  J&J's Innovative Medicine Segment in Q3: Key Growth Drivers to Watch (opens in a new tab)

  Zacks · Oct 2, 2026

• 
  Summit Therapeutics (SMMT), What Is Behind The Fresh Attention? (opens in a new tab)

  Simply Wall St. · Oct 2, 2026

• AstraZeneca, Daiichi Sankyo to Evaluate Datroway Combo Across Tumor Types with Summit Therapeutics (opens in a new tab)

  Yahoo Finance UK · Oct 2, 2026

• Daiichi, AstraZeneca enter clinical trial cooperation with Summit (opens in a new tab)

  London South East · Oct 2, 2026

• AstraZeneca, Daiichi Partner With Summit on Cancer-Drug Trials (opens in a new tab)

  Bloomberg.com · Oct 2, 2026

• AstraZeneca and Daiichi Sankyo Team With Summit on Datroway Combination Trials (opens in a new tab)

  asktraders.com · Oct 2, 2026

• AstraZeneca, Daiichi Sankyo and Summit Therapeutics Plan Datroway–Ivonescimab Combination Trials (opens in a new tab)

  Yahoo Finance UK · Oct 2, 2026

• AstraZeneca, Daiichi Sankyo partner with Summit to test cancer drug combination (opens in a new tab)

  Reuters · Oct 2, 2026

• Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types (opens in a new tab)

  Business Wire · Oct 2, 2026

• 
  Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway (opens in a new tab)

  Business Wire · Oct 2, 2026

• AstraZeneca and Daiichi Sankyo announce clinical collaboration with Summit Therapeutics to evaluate Datroway in combination with ivonescimab across multiple tumour types (opens in a new tab)

  AstraZeneca · Oct 2, 2026

• 
  AstraZeneca (AZN) Puts $2 Billion Into Summit Therapeutics (SMMT) for a Cancer Tie-Up (opens in a new tab)

  Insider Monkey · Oct 2, 2026

• 
  What Does Summit Therapeutics (SMMT) Gain From This $2 Billion Cancer Partnership? (opens in a new tab)

  Simply Wall St. · Oct 1, 2026

• 
  Cellectis Unveils In Vivo Gene-Editing Plans for Severe Lipid Disorders (opens in a new tab)

  MarketBeat · Oct 1, 2026

• Employee schemes bring 9,828 new AstraZeneca (AZN) shares to London Stock Exchange trading. (opens in a new tab)

  Stock Titan · Oct 1, 2026

• REG - AstraZeneca PLC - Admission of Further Securities to Trading (opens in a new tab)

  TradingView · Oct 1, 2026

• APCO appoints ex-Weber Shandwick and AstraZeneca health lead (opens in a new tab)

  PR Week UK · Oct 1, 2026

• Why Is AstraZeneca (LSE:AZN) Stock In Focus Today After Its Summit Therapeutics Investment? (opens in a new tab)

  Kalkine Media · Oct 1, 2026

• Hong Kong needs new funding model to attract global drug makers: AstraZeneca (opens in a new tab)

  South China Morning Post · Oct 1, 2026

• AstraZeneca (LSE:AZN) Oncology Filing Puts Valuation and Growth Back in Focus (opens in a new tab)

  Kalkine Media · Oct 1, 2026

• AstraZeneca signs agreement with Cambridge University Health Partners on using real-world data for better healthcare (opens in a new tab)

  Cambridge Independent · Oct 1, 2026

• 
  700,000 Seniors Have Started GLP-1s Through Medicare. Now AstraZeneca Just Moved a Once-Daily Pill Into Phase 3 (opens in a new tab)

  24/7 Wall St. · Sep 30, 2026

• Is AstraZeneca (LSE:AZN) Undervalued As Its Lung Cancer Filing Draws Fresh Attention? (opens in a new tab)

  Simply Wall Street · Sep 30, 2026

• 
  AstraZeneca’s $2 Billion Vote of Confidence Leaves Summit Therapeutics Trading Well Below Street Targets (opens in a new tab)

  24/7 Wall St. · Sep 30, 2026

• Hansoh’s Tagrisso rival loses EU approval after AstraZeneca legal challenge (opens in a new tab)

  fiercepharma.com · Sep 30, 2026

• AstraZeneca commits $2bn to advance ADC combination medicines for cancer (opens in a new tab)

  European Pharmaceutical Review · Sep 30, 2026

• Drug Repurposing Market - Global Strategic Business Report: Forecasts Growth to $37.3Billion by 2030, Profiling AbbVie, AstraZeneca, Pfizer, Novartis & Johnson & Johnson (opens in a new tab)

  Sep 30, 2026